A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma.
Saved in:
| Title: | A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma. |
|---|---|
| Authors: | Ding, Yangyang1 (AUTHOR), Huang, Keke1 (AUTHOR), Sun, Cheng2 (AUTHOR), Liu, Zelin1 (AUTHOR), Zhu, Jinli1 (AUTHOR), Jiao, Xunyi1 (AUTHOR), Liao, Ya1 (AUTHOR), Feng, Xiangjiang1 (AUTHOR), Guo, Jingjing1 (AUTHOR), Zhu, Chunhua3 (AUTHOR), Zhai, Zhimin1 (AUTHOR) zzzm889@163.com, Xiong, Shudao1 (AUTHOR) xshdao@ahmu.edu.cn |
| Source: | Scientific Reports. 9/11/2024, Vol. 14 Issue 1, p1-15. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20452322 |
|---|---|
| DOI: | 10.1038/s41598-024-72121-8 |
